In the claims:

1. (Previously Presented) A calcium salt of the formula

wherein R_1 is alkyl, cycloalkyl or aralkyl; R_2 , R_3 and R_4 are independently hydrogen, halogen or alkyl; R_5 and R_6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; made by a process comprising:

(1) hydrolyzi ig a compound of the formula

$$R_3$$
 R_4
 R_6
 R_1
 R_2
 R_4
 R_5
 R_1
 R_2
 R_4
 R_5
 R_1
 R_2
 R_4
 R_5
 R_1
 R_2
 R_4
 R_5
 R_1
 R_2
 R_3
 R_4
 R_5
 R_5
 R_7
 R_8
 R_1

wherein R₁, R₂, R₃, I₄, R₅ and R₆ have meanings as defined for formula IA; R represents lower alkyl; and the hydrox yl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; in the presence of an aqueous base to afford an alkali metal salt of the formula

$$R_3$$
 R_4
 R_6
 R_7
 R_8
 R_1
 R_1
 R_2
 R_4
 R_5
 R_7
 R_8
 R_1
 R_1
 R_2
 R_3
 R_4
 R_5
 R_7
 R_8
 R_1
 R_2
 R_3
 R_4
 R_5
 R_7
 R_8
 R_1
 R_2
 R_3
 R_4
 R_5
 R_7
 R_8
 R_7
 R_8
 R_9
 R_9

wherein M represent sodium, lithium or potassium; and

- (2) treating the alkali metal salt of formula IC with a calcium compound to afford the calcium salt of formula IA.
- 2. (Previously Prese ited) The calcium salt according to claim 1, wherein the aqueous base in step (1) is sodium hydroxide and M in formula IC represents sodium and wherein the calcium compound in step (2) is calcium chloride.
- 3. (Previously Prese ited) The calcium salt according to claim 1, wherein R_1 is isopropyl, R_2 is fluorine, and R_3 , R_4 , R_5 and R_6 are hydrogen.
- 4. (Previously Presented) A calcium salt of the formula

$$R_3$$
 R_4
 R_6
 R_7
 R_8
 R_1
 R_4
 R_6
 R_7
 R_8
 R_8
 R_8
 R_9
 R_9

wherein R_1 is alkyl, cycloalkyl or aralkyl; R_2 , R_3 and R_4 are independently hydrogen, halogen or alkyl; R_5 and R_6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; made by treating an alkali metal salt of the formula

$$R_3$$
 R_4
 R_4
 R_6
 R_1
 R_1
 R_2
 R_4
 R_4
 R_5
 R_7
 R_8
 R_1
 R_1
 R_2
 R_3
 R_4
 R_5
 R_6
 R_7
 R_8
 R_8
 R_8
 R_8
 R_8
 R_9
 R_9

wherein R₁, R₂, R₃, I²₄, R₅ and R₆ have meanings as defined for formula IA; M represents sodium, lithium or p stassium; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; with a calcium compound to afford the calcium salt of formula IA.

- 5. (Previously Presented) The calcium salt according to claim 4, wherein M in formula IC represents sodium at d the calcium compound is calcium chloride.
- 6. (Previously Presented) The calcium salt according to claim 4, wherein R_1 is isopropyl, R_2 is fluorine, and R_3 , R_4 , R_5 and R_6 are hydrogen.
- 7. (Original) A crystalline calcium salt of the formula

$$R_{3}$$
 R_{4}
 R_{5}
 R_{4}
 R_{5}
 R_{1}
 R_{2}
 R_{4}
 R_{4}
 R_{5}
 R_{4}
 R_{5}
 R_{1}
 R_{2}
 R_{3}
 R_{4}
 R_{5}
 R_{4}
 R_{5}
 R_{5}
 R_{1}
 R_{2}
 R_{3}
 R_{4}
 R_{5}
 R_{5}

wherein R_1 is isopropyl; R_2 is fluorine; R_3 , R_4 , R_5 and R_6 are hydrogen; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof.

8. (Previously Presented) The crystalline calcium salt according to claim 7, which has a powder X-ray diffraction pattern with maxima at 20 values of 5.3, 11.8, 13.9, 17.5, 19.1, 22.0 and 23.1 and which has a melting point of about 220°C.

9. (Previously Presented) A method for the preparation of a crystalline calcium salt of formula (IA)

$$R_3$$
 R_4
 R_6
 R_6
 R_7
 R_8
 R_1
 R_2
 R_4
 R_4
 R_6
 R_7
 R_8
 R_1
 R_2
 R_4
 R_8
 R_1
 R_2
 R_3
 R_4
 R_8
 R_1
 R_2
 R_3
 R_4
 R_5
 R_7
 R_8
 R_8
 R_8
 R_9
 R_9

wherein R_1 is isopropyl; R_2 is fluorine; R_3 , R_4 , R_5 and R_6 are hydrogen; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof, comprising:

(1) hydrolyzing a compound of the formula

wherein R represents lower alkyl; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; in the presence of an aquec us base to afford an alkali metal salt of the formula

wherein M represents sodium, lithium or potassium; and

- (2) treating the alkali metal salt of formula IE with a calcium compound to afford the crystalline calcium salt.
- 10. (Original) The method according to claim 9, wherein the aqueous base in step (1) is sodium hydroxide and M in formula IE represents sodium and wherein the calcium compound in step (2) is calcium chloride.
- 11. (Previously Presented) A method for the preparation of a crystalline calcium salt of formula (IA)

wherein R_1 is isopropyl; R_2 is fluorine; R_3 , R_4 , R_5 and R_6 are hydrogen; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof, comprising:

treating an al cali metal salt of the formula

wherein M represent sodium, lithium or potassium; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; with a calcium compound to afford the crystalline calcium salt.

- 12. (Original) The method according to claim 11, wherein M in formula IE represents sodium and the calcium compound is calcium chloride.
- 13. (Previously Presented) A pharmaceutical composition, comprising:

a therapeutically effective amount of a calcium salt according to claim 7 in combination with one or more pharmaceutically acceptable carriers.

14. (Previously Presented) A method for treating hypercholesterolemia, hyperlipoproteinemia, dyslipidemia and atherosclerosis, comprising:

administering to a mammal in need thereof a therapeutically effective amount of a calcium salt according to claim 7.

7